1:30
HER2-Low Breast Cancer: Genomic Insights and Evolving Treatment Paradigms | Oncotarget
Oncotarget
2:01
miR-10b Inhibition: A Strategy for Treating Metastatic Breast Cancer | Oncotarget
1:26
Nanobody Inhibits Metastasis of Breast Tumor Cells to Lung in Mice | Oncotarget
1:32
HER2-Low and HER2-Zero in Breast Cancer: Prognosis & Prediction | Oncotarget
1:59
Durvalumab and Tremelimumab Before Surgery in Breast Cancer Patients | Oncotarget
2:17
Sacituzumab Govitecan with Platinum Chemotherapy: Antitumor Effects | Oncotarget
2:27
Risk Factors for Arm Morbidities After Breast Cancer Treatments: A Review | Oncotarget
1:13
The Uncharted Role of HER2 Mutant Alleles in Breast Cancer | Oncotarget
2:02
FAAH Inhibition Ameliorates Breast Cancer in Murine Model | Oncotarget
1:41
Genetic Modifiers of p53: Opportunities for Breast Cancer Therapies | Oncotarget
1:04
The Nuclear Envelope and Metastasis | Oncotarget
Genetic Predisposition to Early Breast Cancer in Women of Kazakh Ethnicity | Oncotarget
1:18
Systemic Treatment for Brain Metastasis in HER2-Positive Advanced Breast Cancer | Oncotarget
Breast Cancer Cell Subpopulations Fueling Invasion and Metastasis | Oncotarget
5:07
ER Expression Multiclonality in DCIS: Clinical & Future Insights | Oncotarget
1:27
Are Cis-Spliced Fusion Proteins Pathological in More Aggressive Luminal Breast Cancer? | Oncotarget
1:19
Multiclonality of ER Expression in DCIS: Implications & Future Research | Oncotarget
1:47
Deciphering Mechanisms of Action of Progesterone in Breast Cancer | Oncotarget
1:48
ERĪ² as Mediator of Estrogen Signaling in Inflammatory Breast Cancer | Oncotarget
1:49
ACSL4: Biomarker, Mediator and Target in Quadruple Negative Breast Cancer | Oncotarget
2:59
BORIS Gene Mutation and Expression: Link to Breast Cancer Progression | Oncotarget
7:00
Behind the Study: Molecular Dialogue Between Tumor Cells and Fibroblasts | Oncotarget
2:33
GPR141 Mediates Breast Cancer Proliferation and Metastasis | Oncotarget
3:07
Role of Biomarkers in Management of Lumps in the Breast | Oncotarget
1:31
Crossroads: The Role of Biomarkers in the Management of Lumps in the Breast | Oncotarget
1:00
EGFR Endocytosis: More Than Meets the Eye | Oncotarget
1:37
Differential Silencing of STAT3 Isoforms Leads to Changes in STAT3 Activation | Oncotarget
1:39
Tumor Necroptosis Promotes Metastasis by Modulating Tumor-Host Immunity | Oncotarget
Crosstalk Between Triple Negative Breast Cancer and Microenvironment | Oncotarget
1:36
Impact of Cortactin in Cancer Progression on Wnt5a/ROR1 Signaling Pathway | Oncotarget
2:06
Polyisoprenylated Cysteinyl Amide Inhibitors Deplete G-Proteins in Cancer Cell Lines | Oncotarget
2:25
MTAP Loss in Metastatic Breast Cancer Patients: Genomic Landscape | Oncotarget
1:51
āExtreme Phenotype Approachā Applied to Male Breast Cancer Allows ID of Rare Variantsā¦ | Oncotarget
1:52
Resistance of MMTV-NeuT/ATTAC Mice to Anti-PD-1 Immune Checkpoint Therapy | Oncotarget
7:50
APOE Genotype & Exercise Benefits in Cancer Patients | Oncotarget
APOE Genotype Determines Cancer Patients Most Likely to Benefit From Exercise | Oncotarget
Therapeutic Efficacy of H2aL2a, H3L3 in Xenograft Models of Human Breast, Lung Cancer | Oncotarget
9:23
Inhibition of Resistant Triple-negative Breast Cancer Cells | Oncotarget
1:40
Continuous Abemaciclib Treatment Leads to Breast Cancer Inhibition | Oncotarget
1:21
Endocrine Resistance-Causing Genes in Breast Cancer | Oncotarget
1:12
Breast Cancer Survivors and Weight Loss | Oncotarget
Oncotarget | NOTCH1 Variants in Triple-Negative Breast Cancer
0:56
Oncotarget | Pre-Treatment Ultrasound Used to Predict Breast Cancer Recurrence
0:49
Oncotarget | Neutrophil Density Associated With Breast Cancer Prognosis
6:46
Oncotarget | Innovating & Expanding Weight Loss Strategies for Breast Cancer Survivors
0:55
Oncotarget | Benzophenone-3 Promotes Breast Cancer in Diet-Dependent Manner
9:04
Oncotarget: Benzophenone-3 Promotion of Mammary Tumorigenesis is Diet-dependent
0:57
Oncotarget: Clinical Trial of P10s-PADRE Vaccine in Breast Cancer
0:42
Oncotarget: MEND Study Analysis of Nigerian Breast Cancer
0:54
Oncotarget: MRI Features Predict Treatment Response in Breast Cancer
0:46
Oncotarget: Sacituzumab Govitecan in Triple-Negative Breast Cancer
0:53
Oncotarget: Akt Antagonist Drug and Th1 Cytokines Combat Breast Cancer
29:39
Oncotarget: Breast cancer cells to ONC201 from anti-proliferative to apoptotic
0:41
Oncotarget: Combination Therapeutics Inhibit Breast Cancer Resistance
0:59
Oncotarget: CRISPR Used in Triple Negative Breast Cancer Research
Oncotarget: Phenotypic Changes in HER2+ Breast Cancer
Oncotarget: Benign, Borderline, and Malignant Breast Tumors
4:54
Oncotarget: Osteoprotegerin rich tumor microenvironment: implications in breast cancer
7:39
Oncotarget: Camptothecin targets WRN protein: in clinical breast cancer
Oncotarget: AKT1(E17K) mutation induces mammary hyperplasia but prevents HER2-driven tumorigenesis
4:56
Oncotarget: LINC00520 is induced by Src, STAT3, and PI3K in breast cancer
7:24
Oncotarget: Researchers identify potential therapeutic target in aggressive breast cancer cells
8:10
Oncotarget: Prognostic role of elevated mir-24-3p in breast cancer
28:49
Oncotarget: Anti-psychotic drug could treat aggressive breast cancer
11:32
University of Vermont Cancer Center's Marie Wood talks about their publication in Oncotarget
8:39
Secretomes from Metastatic Breast Cancer Cells and MSC Actions | Oncotarget
12:54
Oncotarget: ONC201 kills breast cancer cells in vitro by targeting mitochondria
